IPSEF News and Press, Ipsen From 04/24/25

Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options Patients treated with elafibranor versus placebo showed significant improvements in liver ...

2025-04-16 11:33:04 ET Ipsen S.A. (IPSEY) Q1 2025 Results Conference Call April 16, 2025 08:00 AM EDT Company Participants David Loew - Chief Executive Officer Aymeric Le Chatelier - Chief Financial Officer Conference Call Participants Shan Hama - Jefferi...

Total sales growth of 11.6% at CER 1 , or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay. Tovorafenib regulatory submission to EMA 2 for pediatric low-grade glioma. Confirmation of full-year 2025 financi...

2025-04-01 12:18:53 ET More on Eton Pharmaceuticals Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript Eton Pharmaceuticals receives new U.S. patent for ET-600 FDA extends target action date for Eton's ET-400 Seeking A...

Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today announced the successful completion of its inaugural Rated Public Bond ...

PARIS, FRANCE, March 12 th , 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1 st , 2025.  She will serve on Ipsen’s Executive Leadership Te...

2025-02-13 11:25:17 ET More on Ipsen S.A., Ipsen S.A., etc. Ipsen S.A. (IPSEY) Q4 2024 Earnings Call Transcript Historical earnings data for Ipsen S.A. Dividend scorecard for Ipsen S.A. Financial information for Ipsen S.A. Historical earnings data for...

2025-02-13 11:24:41 ET Ipsen S.A. (IPSEY) Q4 2024 Earnings Call February 13, 2025 07:00 ET Company Participants David Loew - Chief Executive Officer Aymeric Le Chatelier - Chief Financial Officer Christelle Huguet - Head, R&D Conference Call Participant...

2025-02-13 01:58:08 ET More on Ipsen S.A.: Historical earnings data for Ipsen S.A. Dividend scorecard for Ipsen S.A. Financial information for Ipsen S.A. Read the full article on Seeking Alpha For further details see: Ipsen S.A. Non-GAAP EPS of &#...

FY 2024 total sales growth of 9.9% at CER 1 , or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% in Neuroscience, and 7.3% in Oncology; Somatuline ® (lanreotide) sales grew by 5.6...